A new article in iScience reports that the selective inhibition of ALDH1A3 can markedly impede breast cancer growth and metastasis by blocking ALDH1A3-driven transcriptional programs.
Beyond reinforcing ALDH1A3 as a central driver of aggressive tumour behavior, the study highlights an important therapeutic principle: shutting down the downstream gene-expression programs orchestrated by ALDH1A3 can translate into meaningful anti-tumour effects in pre-clinical settings.
For Theranib, it is a timely and highly relevant contribution to the field, strengthening the rationale for ALDH1A3-selective strategies as a route to stop disease progression and metastatic dissemination.